Gill, Taylor
Wang, Haichuan
Bandaru, Raj
Lawlor, Matthew http://orcid.org/0000-0003-0700-5763
Lu, Chenyue
Nieman, Linda T.
Tao, Junyan
Zhang, Yixian
Anderson, Daniel G.
Ting, David T. http://orcid.org/0000-0002-3261-2322
Chen, Xin http://orcid.org/0000-0002-9588-0164
Bradner, James E. http://orcid.org/0000-0002-2718-4415
Ott, Christopher J. http://orcid.org/0000-0001-6142-7241
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00CA190861, P30-CA14051)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 18 February 2021
Revised: 7 September 2021
Accepted: 30 September 2021
First Online: 14 October 2021
Competing interests
: CJO, RB, YZ, and JEB are listed as inventors in an issued patent related to the compounds described in this manuscript (WO2013123451A1). D.T.T. has received consulting fees from ROME Therapeutics, Foundation Medicine, Inc., NanoString Technologies, EMD Millipore Sigma, Pfizer, and Third Rock Ventures that are not related to this work. DTT is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc., which is not related to this work. DTT receives research support from ACD-Biotechne, PureTech Health LLC, and Ribon Therapeutics, which was not used in this work. Dr. Ting’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. JEB is now an executive and shareholder of Novartis and has been a founder and shareholder of SHAPE (acquired by Medivir), Acetylon (acquired by Celgene), Tensha (acquired by Roche), Syros, Regenacy and C4 Therapeutics.